Biosency
Biosency develops Bora care®, a CE MDR-certified remote monitoring and predictive medicine platform for COPD patients, combining a connected wristband, cloud software, and a proprietary BVS³ AI algorithm that predicts exacerbations 4.4 days in advance. It sells to pulmonologists and hospitals in France and Europe via direct sales and channel partners.
- Company typePrivate
- Founded2017
- HeadquartersRennes, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Biosency does
Biosency is a French medical device company founded in July 2017 by Marie Pirotais and Yann Le Guillou, headquartered in the Rennes metropolitan area. It develops Bora care®, an integrated remote monitoring and predictive medicine solution for patients with chronic respiratory insufficiency, principally Chronic Obstructive Pulmonary Disease (COPD). The system combines a CE MDR Class IIa-certified connected wristband (Bora band®) that captures SpO2, heart rate, respiratory rate, and skin temperature, with a Bora box data transmission accessory and the Bora connect® cloud platform, which visualizes vital signs, tracks intelligent alerts, and integrates with healthcare professional workflows via SDK/API. Its core differentiator is the proprietary BVS³ predictive algorithm, validated across 8 clinical trials and 14 international scientific publications to predict COPD exacerbations approximately 4.4 days in advance with 86% sensitivity and 9% false positives, supported by 6 patent families and over 500,000 days of accumulated monitoring data.
Biosency sells through a hybrid model combining direct sales to pulmonologists and respiratory specialists with channel partnerships — most notably ResMed (France, Maghreb, certain European countries, signed October 2022), Duomed France (exclusive domestic distribution, signed November 2025), and Inogen (oxygen-therapy patients, signed January 2026). Revenue streams include hardware sales of the Bora band®, subscription-based remote monitoring services via Bora connect®, and the Bora flow module, which is certified compliant with HAS and ANS requirements and eligible for reimbursement by French Health Insurance. Pricing is not publicly disclosed. The company has accumulated €21 million in total funding (€14M dilutive, €7M non-dilutive) since founding, with the most recent €7M round closed in November 2023 from existing investors including Go Capital. In June 2026, Biosency was acquired by Withings, a connected-health platform, marking a strategic exit that integrates its respiratory monitoring capability into a broader consumer and clinical health ecosystem.
Biosency firmographics
Firmographics- Name
- Biosency
- Legal name
- BIOSENCY, SAS
- Website
- https://biosency.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Biosency develops Bora care®, a CE MDR-certified remote monitoring and predictive medicine platform for COPD patients, combining a connected wristband, cloud software, and a proprietary BVS³ AI algorithm that predicts exacerbations 4.4 days in advance. It sells to pulmonologists and hospitals in France and Europe via direct sales and channel partners.
- Ownership category
- akta.pro rank
Biosency industry classification
Industry- Product category
- Remote Patient Monitoring
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Misc Health & Allied Services, Nec (8090), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- COPD & Chronic Bronchitis Management (HLAKANAE)
- akta.pro secondary industries
- Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management (HLAKANAM), Home Respiratory & Sleep Therapy Providers (DME-Integrated) (HLAFAEAF), Pulmonology & Sleep Medicine Telemedicine Platforms (HLALAGAF)
Keywords
Where Biosency is headquartered
LocationHeadquarters
- HQ city
- Rennes
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Biosency business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Remote Monitoring Services: Subscription-based remote patient monitoring services through Bora connect® platform, providing continuous vital sign monitoring and predictive alerts for COPD patients. Revenue derived from healthcare provider subscriptions for access to the platform and monitoring services.
- Bora band® Medical Device Sales: Sale of Bora band® connected wristband - a Class IIa medical device for measuring and monitoring vital signs in patients with respiratory insufficiency. Device sold to healthcare providers and patients for home use.
- Bora flow Module: Remote monitoring module for patients on respiratory assistance, certified compliant with HAS and ANS requirements, eligible for reimbursement by French Health Insurance.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Biosency product offering
Product offeringCore offering
Biosency develops and commercializes Bora care®, an integrated remote patient monitoring and predictive medicine solution for COPD and chronic respiratory insufficiency patients. The offering combines the Bora band® connected wristband (Class IIa CE MDR certified medical device measuring SpO2, heart rate, respiratory rate, and skin temperature), the Bora connect® cloud platform for healthcare professionals, the Bora flow module for respiratory assistance monitoring, and the proprietary BVS³ predictive algorithm that anticipates COPD exacerbations approximately 4.4 days in advance. The solution is sold primarily to pulmonologists, hospitals, and respiratory care centers across Europe, with selective distribution partnerships.
Product overview
Biosency offers Bora care®, an integrated remote monitoring and predictive medicine solution for COPD patients. The portfolio consists of Bora connect® cloud platform (for data visualization and alert management), Bora band® connected wristband (for vital signs collection), and Bora flow module (for respiratory assistance monitoring). Additional components include Bora box (data transmission device) and Bora partner (SDK/API integration option). The BVS³ AI algorithm provides predictive analytics to detect COPD exacerbations approximately 4.4 days before they occur. All components are CE MDR Class IIa certified.
Differentiator
Problem solved
Functional benefit
Brands
- Bora care®: Integrated home monitoring solution for COPD patients, combining remote monitoring and predictive medicine
- Bora connect®
- Bora flow
- Bora band®
- Bora box
- BVS3®
Products and services
- Bora care® Integrated home monitoring solution combining the Bora band® wristband, Bora connect® cloud platform, and Bora flow module to deliver remote monitoring and predictive medicine for COPD and chronic respiratory insufficiency patients. The solution enables early detection of exacerbations via the BVS³ predictive score and is CE MDR Class IIa certified. It is sold to pulmonologists, hospitals, and respiratory care centers.
- Bora connect® Cloud-based platform available via web browser and mobile application for healthcare professionals. Provides visualization of vital signs and respiratory assistance machine data, customizable parameters, intelligent alert tracking, and SDK/API for third-party integration. Targets pulmonologists, respiratory therapists, and care teams managing chronic respiratory patients.
- Bora band® Connected wristband that collects vital signs (SpO2, heart rate, respiratory rate, skin temperature) in real life for remote monitoring of patients with respiratory insufficiency. Lightweight, waterproof (IP64), with up to 5 days battery life and single-button operation. CE MDR Class IIa certified, produced exclusively in France. Sold to healthcare providers and prescribed for home use by COPD and chronic respiratory patients.
- Bora flow Remote monitoring module for patients on respiratory assistance, providing a clinical dashboard with customizable alerts for healthcare professionals. Enables compliance tracking and health status change detection for patients using respiratory assistance devices. Certified compliant with HAS and ANS requirements and eligible for reimbursement by French Health Insurance.
Quantifiable outcome
- COPD exacerbations detected approximately 4.4 days before they occur
- +3 more outcomes
Companies that use Biosency
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Biosency technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Biosency partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- WithingsflagshipBiosency announced it is joining Withings, a leading player in connected health. This acquisition marks a significant step in Biosency's development, reflecting shared ambition to accelerate innovation in remote respiratory monitoring, strengthen impact of remote monitoring solutions, and advance preventive, continuous, and accessible healthcare.
- InogencoreStrategic collaboration with Inogen, world leader in portable oxygen concentrators, to create the first remote monitoring solution with automated data transmission for patients on oxygen therapy. Enables remote monitoring of patients on oxygen therapy through a unique medical platform designed with and for healthcare professionals.
- Duomed FrancecoreExclusive partnership with Duomed France, a major medical device distributor in France, to accelerate deployment of Bora care® and facilitate access to the solution for healthcare professionals. Aims to enhance monitoring of patients with respiratory failure, particularly COPD patients.
- ResMedcoreStrategic partnership with ResMed, world leader in innovative solutions for treatment of respiratory disorders. ResMed distributes Bora care® remote monitoring solution to healthcare professionals in France, Maghreb, and certain European countries for patients with respiratory failure.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Biosency competitors and assessment
Company assessmentDirect peers
- Vivify Health: Remote patient monitoring platform supporting multiple chronic conditions including COPD, with mobile kits and integration into health system workflows. Comparable RPM platform play.
- Propeller Health: Direct competitor in respiratory remote monitoring focused on asthma and COPD medication adherence and exacerbation prediction. Acquired by ResMed in 2019, making it the closest direct peer in COPD/asthma RPM.
- HGE Health: Digital health company offering remote monitoring specifically for COPD patients, with predictive algorithms to reduce hospitalizations. Closely aligned niche and use case as Biosency's Bora care®.
- CareSimple: RPM platform offering cellular-connected vital sign monitoring for chronic conditions including COPD, sold to health systems and home health agencies in North America and Europe.
- Adherium: Digital health company focused on respiratory remote monitoring, particularly asthma and COPD medication adherence sensors and patient management platforms. Comparable niche in connected respiratory drug delivery.
Emerging players
- Tytocare: Telehealth and remote examination device company with overlapping RPM and chronic care management capabilities, including respiratory assessment, serving providers and payors.
- Smart Respiratory Products: Smaller emerging player building connected respiratory devices and adherence/symptom monitoring tools. Competes in adjacent connected inhaler and respiratory monitoring use cases.
Broad incumbents
- ResMed: Global leader in sleep and respiratory care devices, including CPAP and ventilation equipment. ResMed is both a strategic partner (distributes Bora care®) and a broad incumbent competing in respiratory patient management, having acquired Propeller Health for asthma/COPD RPM.
- Philips: Diversified medtech incumbent with a large respiratory and sleep portfolio (ventilators, CPAP) plus connected care/telehealth offerings. Competes in the broader hospital-to-home respiratory care continuum.
Others
- Withings: Leading connected health device maker (smart scales, watches, sleep mats) and now Biosency's parent company. Comparable as a connected health platform player and ecosystem participant in RPM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Biosency social profiles
Digital presenceBiosency compliance and trust
Trust signalCompliance6 records
Biosency financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biosency leadership team
Management profileNumber of profiles
Profiles3 records
Biosency funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biosency M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biosency
What does Biosency do?
Biosency develops and commercializes Bora care®, an integrated remote patient monitoring and predictive medicine solution for COPD and chronic respiratory insufficiency patients. The offering combines the Bora band® connected wristband (Class IIa CE MDR certified medical device measuring SpO2, heart rate, respiratory rate, and skin temperature), the Bora connect® cloud platform for healthcare professionals, the Bora flow module for respiratory assistance monitoring, and the proprietary BVS³ predictive algorithm that anticipates COPD exacerbations approximately 4.4 days in advance. The solution is sold primarily to pulmonologists, hospitals, and respiratory care centers across Europe, with selective distribution partnerships.
Is Biosency a public or private company?
Biosency is a private company. It is classified as corporate owned and is currently acquired.
When was Biosency founded?
Biosency was founded in 2017. It employs 11 to 50 people.
Where is Biosency based?
Biosency is headquartered in Rennes, France, in the Europe region.
How does Biosency make money?
Three revenue lines are on record. Remote Monitoring Services are the primary driver. The others are bora band® Medical Device Sales and bora flow Module.
Who are Biosency's main competitors?
Direct peers on record are Vivify Health, Propeller Health, HGE Health, CareSimple and Adherium. Emerging players are Tytocare and Smart Respiratory Products. Broad incumbents are ResMed and Philips. Withings is listed as an others.
Does Biosency have an API?
Yes. Bora connect® platform interfaces with other platforms via SDK/API. The Bora partner option enables the Bora band® to be integrated into third-party remote monitoring platforms, with data from the wristband sent via SDK/API. No public documentation URL, pricing, or developer portal specified.
What industry is Biosency in?
Biosency's product category is Remote Patient Monitoring. Its primary akta.pro industry code is HLAKANAE, COPD & Chronic Bronchitis Management, with a secondary code of HLAKANAM, Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management. Its NAICS code is 5417 and its SIC code is 8090.